NEW YORK – Having recently completed a $12 million Series A funding round, liquid biopsy spinout C2i Genomics plans to initiate several retrospective and prospective validation trials on its minimal residual disease (MRD) detection platform, MRDetect, with undisclosed clinical centers in the US and Europe over the next year.
The New York-based firm believes MRDetect could be used to help physicians evaluate MRD status in a patient following tumor resection.